Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

94.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
66 67 Next >
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
Via Benzinga
Exposures COVID-19
What's Going On With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday. 
Via Benzinga
What's Happening With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 3.28% to $101.73 Tuesday afternoon as the stock rebounds after falling on Monday. 
Via Benzinga
BioNTech Se (BNTX) Q2 2023 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling. 
Via The Motley Fool
Why Moderna Stock Sunk Today
Moderna, Inc. (NASDAQ: MRNA) shares are trading lower on Monday. 
Via Benzinga
BioNTech Skids As Covid Vaccine-Maker's Sales Plummet And Miss Forecasts
The company kept its sales outlook for the year, however. 
Via Investor's Business Daily
Preview: BioNTech's Earnings
Via Benzinga
Analyst Ratings for BioNTech
Via Benzinga
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement
Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere. 
Via Talk Markets
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23
BioNTech SE (NASDAQ: BNTX) has reported Q2 revenues of €167.7 million, sharply down from €3.2 billion a year ago 
Via Benzinga
US Stocks Eye Rebound After Big Earnings, But Inflation Data Looms: Analyst Says 3 Factors Can Take S&P 500 Past 4,800
US stocks look set for a cautious start as the week's inflation data will likely keep traders on tenterhooks. 
Via Benzinga
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Expert Ratings for BioNTech
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
Where BioNTech Stands With Analysts
Via Benzinga
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.
The company hopes to launch an updated Covid booster shot this fall. But there are several complications. 
Via Investor's Business Daily
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
3 Biotech Stocks That AI is Loving in July
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness
The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually... 
Via Benzinga
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets
With the artificial intelligence boom gaining momentum, we’re likely to see far more interest in AI stocks. 
Via InvestorPlace
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support
Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.